

Image-based & machine learning-guided multiplexed serology test for SARS-CoV-2

Authors

Vilja Pietiäinen^{** 1}, Minttu Polso^{* 1}, Ede Migh^{* 2}, Christian Guckelsberger^{* 1, 3, 4, 5}, Maria Harmati², Akos Diosdi², Laura Turunen¹, Antti Hassinen¹, Swapnil Potdar¹, Annika Koponen^{6, 7}, Edina Gyukity Sebestyen², Ferenc Kovacs^{2, 8}, Andras Kriston^{2, 8}, Reka Hollandi², Katalin Burian⁹, Gabriella Terhes⁹, Adam Visnyovszki¹⁰, Eszter Fodor¹¹, Zsombor Lacza¹¹, Anu Kantele^{12, 13}, Pekka Kolehmainen¹⁴, Laura Kakkola¹⁴, Tomas Strandin¹⁵, Lev Levanov¹⁵, Olli Kallioniemi^{1, 16}, Lajos Kemeny¹⁷, Ilkka Julkunen^{14, 18}, Olli Vapalahti^{15, 19, 20}, Krisztina Buzas^{2, 21}, Lassi Paavolainen¹, Peter Horvath^{*,** 1, 2, 8}, and Jussi Hepojoki^{*,** 15, 22}

^{*)} equal contributions

^{**)} corresponding authors

Vilja Pietiäinen, Tukholmankatu 8, Institute for Molecular Medicine Finland (FIMM), Biomedicum Helsinki 2U, P.O.Box 20, Tukholmankatu 8, FI-00014 University of Helsinki, Finland. Tel. +358 40 5102546, vilja.pietiainen@helsinki.fi

Affiliations

- 1) Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland
- 2) Laboratory of Microscopic Image Analysis and Machine Learning, Institute of Biochemistry, Biological Research Centre, Szeged, Hungary
- 3) Department of Computer Science, Aalto University, Espoo, Finland
- 4) Finnish Center for Artificial Intelligence, Espoo, Finland

- 5) School of Electronic Engineering and Computer Science, Queen Mary University of London, London, United Kingdom
- 6) Minerva Foundation Institute for Medical Research, Helsinki, Finland
- 7) Department of Anatomy, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- 8) Single-Cell Technologies Ltd., Szeged, Hungary
- 9) Department of Medical Microbiology, Faculty of Medicine, University of Szeged, Szeged, Hungary,
- 10) 1st Department of Internal Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary
- 11) Department of Sports Physiology, Inst. Sports and Health Sciences, University of Physical Education, Budapest, Hungary
- 12) Meilahti Infectious Diseases and Vaccine Research Center, MeiVac, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- 13) Human Microbiome Research Program, University of Helsinki, Helsinki, Finland
- 14) Institute of Biomedicine, University of Turku, Turku, Finland
- 15) Department of Virology, Medicum, University of Helsinki, Helsinki, Finland
- 16) Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden
- 17) HCEMM-USZ Skin Research Group, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
- 18) Turku University Hospital, Turku, Finland
- 19) Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
- 20) HUS Diagnostic Center, HUSLAB, Clinical Microbiology, Helsinki University Hospital, Helsinki, Finland
- 21) Department of Immunology, Faculty of Medicine, Faculty of Science and Informatics, University of Szeged, Szeged, Hungary
- 22) University of Zurich, Vetsuisse Faculty, Institute of Veterinary Pathology, Zürich, Switzerland

Classification. 1. Biological Sciences/Immunology and Inflammation 2. Physical sciences/Biophysics and Computational Biology

Keywords. antibody response, COVID-19, high-content imaging, immunofluorescence assay, machine-learning, SARS-CoV-2, serology, virus

Public abstract. The manuscript describes a miniaturized immunofluorescence assay (mini-IFA) for measuring antibody response in patient blood samples. The automated method builds on machine-learning -guided image analysis with SARS-CoV-2 as the model pathogen. The method enables simultaneous measurement of IgM, IgA, and IgG responses against different virus antigens in a high throughput manner. The assay relies on antigens expressed through transfection and allows for differentiation between vaccine-induced and infection-induced antibody responses. The transfection-based antigen expression enables performing the assay at a low biosafety level laboratory and allows fast adaptation of the assay to emerging pathogens. Our results provide proof-of-concept for the approach, demonstrating fast and accurate measurement of antibody responses in a clinical and research set-up.

1 **Abstract**

2

3 Here, we describe a scalable and automated, high-content microscopy -based mini-
4 immunofluorescence assay (mini-IFA) for serological testing i.e., detection of antibodies.
5 Unlike conventional IFA, which often relies on the use of cells infected with the target
6 pathogen, our assay employs transfected cells expressing individual viral antigens. The
7 assay builds on a custom neural network-based image analysis pipeline for the
8 automated and multiplexed detection of immunoglobulins (IgG, IgA, and IgM) in patient
9 samples. As a proof-of-concept, we employed high-throughput equipment to set up the
10 assay for measuring antibody response against severe acute respiratory syndrome
11 coronavirus 2 (SARS-CoV-2) infection with spike (S), membrane (M), and nucleo (N)
12 proteins, and the receptor-binding domain (R) as the antigens. We compared the
13 automated mini-IFA results from hundreds of patient samples to the visual observations
14 of human experts and to the results obtained with conventional ELISA. The comparisons
15 demonstrated a high correlation to both, suggesting high sensitivity and specificity of the
16 mini-IFA. By testing pre-pandemic samples and those collected from patients with RT-
17 PCR confirmed SARS-CoV-2 infection, we found mini-IFA to be most suitable for IgG and
18 IgA detection. The results demonstrated N and S proteins as the ideal antigens, and the
19 use of these antigens can serve to distinguish between vaccinated and infected
20 individuals. The assay principle described enables detection of antibodies against
21 practically any pathogen, and none of the assay steps require high biosafety level

1 environment. The simultaneous detection of multiple Ig classes allows for distinguishing
2 between recent and past infection.

3

4 **Main text**

5

6 Serological assays are essential for studying and controlling infectious disease outbreaks,
7 such as the current COVID-19 (coronavirus disease 2019) pandemic caused by severe
8 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Immunofluorescence assays
9 relying on cells infected with a given virus provide rapidly available means for
10 demonstrating antibody response against emerging pathogens. However, setting up such
11 assays may require a high biosafety level facility for handling the virus¹. In addition, such
12 assays are often low-throughput and interpretation of the results is labor-intensive and
13 subjective. Here, we describe a mini-immunofluorescence assay (mini-IFA), which is a
14 machine learning-guided, microscopy-based, automated, high-throughput serology
15 assay, requiring a low biosafety level environment, and demonstrate its' efficacy using
16 SARS-CoV-2 as a model (**Fig. 1**).

17

18 **Method**

19 **Assay set-up and automation.**

20 *Laboratory method* (Steps 1–4, **Fig. 1a**; **Supp. Text File 1** for the standard operating
21 procedure). The cell line of interest (here: African green monkey kidney cells, Vero E6) is
22 separately transfected with plasmids encoding four SARS-CoV-2 antigens (spike protein
23 [S] with a His-tag; S-pCAGGS², membrane protein [M] with an HA-tag; M-pEBB,

1 nucleoprotein [N] with a His-tag; NP-pCAGGS³, and the receptor-binding domain, RBD
2 [R], of S protein with His-tag; RBD-pCAGGS²) (see **Supp. Text File 2** for Materials &
3 **Methods, and Table S1**). The transfected cells in suspension are transferred to 384-well
4 assay plates with high-throughput automation. Transient transfection, as opposed to
5 stable transfection, allows simultaneous control of the background signal and detection
6 of autoantibodies, based on non-transfected cells included in the same well. Patient sera
7 and assay controls (**Fig. 1b; Fig. S1**), as well as a DNA binding dye (Hoechst 33342),
8 are added to the wells with an acoustic dispenser to simultaneously monitor the accuracy
9 and success of the sample transfer. Each of assays (and plates) includes several positive
10 (and negative) controls, which allow for comparing the results between assays and the
11 measurement of transfection percentage, enabling cross-assay standardization.
12 Immunoglobulin (Ig) classes present in the samples are detected by multiplexed
13 immunostaining with fluorescent-labelled antibodies for IgM (AlexaFluor; AF; AF488), IgG
14 (DyLight; DL; DL550), and IgA (AF647). Transfection efficiency (**Table S2**) is controlled
15 by staining with antibodies (**Table S1**) targeting the respective (His/HA -tagged) antigens
16 and/or antigen specific antisera. We image four different fluorescent channels with high-
17 content microscopy to detect a) *IgG*, b) *IgA*, c) *IgM*) and d) the cell nuclei (**Fig. 1b-c; Fig.**
18 **S1**). The method can be modified to include any antibodies/markers; however, any new
19 marker will require a new training set for machine-learning models (see later assay
20 adaptability & semi-automated method). Here, we excluded the cytoplasmic marker to
21 include the transfection controls/additional Ig classes to the basic four channel
22 microscopy set-up.

1 *Computational Analysis (Steps 5-8, Fig. 1A)*. The analysis pipeline includes the
2 processing of the microscopy images, per-cell and per-well predictions, and the
3 visualization of the results. The images were processed with the BIAS software^{4,5},
4 facilitating pre-processing⁶, deep learning-based cell segmentation⁷ (**Fig. 1d**), and feature
5 extraction (**Supp. Text File 2**). We developed dedicated Python scripts to use these
6 features for the prediction of antibody response through supervised machine-learning
7 (GitHub: https://github.com/fimm-covid-19-hca/mini-IFA_paper). More specifically, we
8 trained models to classify each segmented immunostaining phenotype - represented by
9 the extracted image features - into five classes: “positive”, “negative”, “atypical”, “small
10 bright”, and “trash” (**Fig. 1e, Fig. S2; class design rationale in Supp. Text File 2**). As
11 training data, we labelled 55496 cells across 16 plates (four plates for each antigen), with
12 roughly equal proportions per antigen (**Table S3**). Labels were assigned in BIAS
13 software^{4,5} as previously described⁸, using an active learning feature⁹ to increase training
14 data quality. We avoid model bias through class imbalances by including class weights in
15 the training. To account for potential signal variations across plates and batches, image
16 features were normalized based on per-plate controls. We employed leave-one-plate-out
17 cross-validation to (i) determine the best out of three normalization approaches and (ii)
18 select the best classification model and hyperparameters for each Ig class-antigen pair.
19 Performance was scored on prediction sensitivity x specificity, and one plate was left out
20 as validation set in each fold to assess the method’s generalization potential as prediction
21 quality on unseen plates – a typical scenario for the assay’s clinical application. We found
22 that the model can classify individual cells accurately with specificity 0.96-0.97, 0.95-0.96,
23 0.96-0.97 and sensitivity 0.84-0.89, 0.79-0.84, 0.82-0.86, for IgG, IgA and IgM,

1 respectively (**Supp. Text File 2, Fig. S3a-b, and Table S4**). Following this selection, we
2 re-trained the best classification model/hyperparameter configuration on the entire
3 training dataset, processed with the best normalization scheme. We applied the trained
4 model to a separate experimental test dataset including samples from four plates,
5 separately for each antigen to produce per-cell predictions. Based on these predictions,
6 we calculated a per-well positivity score as the ratio of predicted positive cells over all
7 segmented cells. The user can define the cut-off of this value based on positive and
8 negative controls (See **Supp. Data 1** for data visualization graphs showing the sample
9 distribution as compared to the positive and negative controls), resulting in binary per-
10 well antibody response predictions.

11
12 *Visualization.* Quality control (QC) assessment with an automated script is available to
13 control the assay's quality, including cell seeding and sample transfer accuracy, as well
14 as signal distribution for positive and negative controls (**Fig. S4**). The data are visualized
15 with (interactive) plots and heatmaps (**Supp. Data 1-2**).

16
17 *Adaptability and scalability of the assay.* To 1) evaluate the assay's technical scalability
18 and adaptability to a laboratory without advanced automation and to 2) test a variation
19 that measures the IgG/IgA signal only in antigen transfected cells (recognized with his-
20 tag), either shipped ready-to-go assay plates (cells transfected with the virus antigen and
21 fixed) or manually prepared assay plates were utilized in another laboratory (Biological
22 Research Centre, Szeged, Hungary; see **Supp. Text File 2** and **Fig. S5** for Semi-

1 automated method). Single cell phenotypic analysis was performed with BIAS software
2 as described⁵. The results are displayed in detail at **Supp. Text File 3** and **Fig. S8-S9**.
3 Altogether, we processed 948 (583 FIMM) serum or plasma specimens collected in 2017
4 and 2020, with ethics approvals and informed consent (**Supp. Text File 2, Table S5**) from
5 890 (545 FIMM) donors, of which 181 (42 FIMM) were individuals with a positive SARS-
6 CoV-2 RT-PCR and/or ELISA test result.

7
8 *Assay results.* As the results include thousands of data points, we developed automated
9 scripts for the visualization of the quality assessment, as well as for the assay results.
10 The visualization includes assay control data and plate-based heatmaps (**Fig. S4**). The
11 results, allowing the observer to view images of each (patient) sample separately for all
12 Ab/Ag scores, are visualized as interactive plots (plate-based; **Supp. Data 1**). The plots
13 allow the clicking of the data point and opening of the image of the selected sample
14 in a separate window for additional visual evaluation, and as heatmaps (**Supp. Data 2**).
15 These enable a fast digital (re)view of the results, independent of place and time, with
16 quantitatively scored findings, and the fast prioritization of the serum samples for
17 further tests, e.g., for a neutralizing assay or for the re-evaluation of technically
18 challenging samples or borderline cases.

19 As shown in **Fig. 2a**, the assay could distinguish between serum samples from donors
20 measured SARS-CoV-2 positive (COVID-19) and negative samples (Neg) in RT-PCR
21 with a high level of significance as indicated by low p-values (**Table S6**). The p-values
22 were lowest for the N and S proteins, for both IgA and IgG. IgM produced the least specific
23 responses (**Fig. S6a, Table S6**), mostly explained by the appearance of unspecific

1 staining in some samples. For IgA against the SARS-CoV-2 M protein, rarely employed
2 in ELISA tests, our assay gave a high signal (i.e., positive ratio) for samples taken within
3 <2 weeks of the positive RT-PCR test result (**Fig. 2a**). Based on these findings, the assay
4 enables the simultaneous determination of different Ig class responses against multiple
5 antigens. This is beneficial 1) for the separation of SARS-CoV-2 positive and negative
6 cases, 2) for retrospective timing of the development of the infection and immunity against
7 it, and 3) for distinguishing between vaccine- and infection-induced Ig responses.

8
9 *Comparison of expert opinion.* An indirect immunofluorescence assay is commonly
10 carried out on virus-infected cells fixed on glass slides, for which the findings rely on the
11 expert's visual inspection under a fluorescence microscope. To evaluate the quality of our
12 per-well predictions, we performed a comparison against the consensus finding of six
13 experts' visual inspection. We randomly selected a balanced number of images (IgG/IgA
14 x S/N/R plates) to represent the antibody reactivity for SARS-CoV-2 antigens of both
15 expected positive (COVID-19 patient sera) and expected negative (samples collected in
16 2017, see **Table S5**) cases. Images from IgM and M-protein plates were not included due
17 to unspecific or unclear staining patterns. Six experienced virologists/cell biologists
18 annotated a set of 576 images as positive, negative, or unclear, one by one (**Fig. S7**). 26
19 images for which the experts did not reach a consensus (majority vote: all IgA, with 23
20 opinions for IgA R-antigen) were removed from the evaluation. Model quality was
21 assessed by measuring the area under the receiver operating characteristic curve (AUC)
22 (**Fig. 2b**), which relates to the prediction's sensitivity and specificity, and is considered
23 optimal at a value of 1. For IgG, the model performed at an AUC of 0.98, 0.97, and 0.98,

1 and for IgA it performed at an AUC of 0.96, 0.96, and 0.89 for S, N, and R antigens,
2 respectively.

3 *Comparison to ELISA assay results.* Next, we compared our per-well predictions to the
4 results of SARS-CoV-2 ELISA tests (IgG, IgA, and IgM against N, R and S, see **Supp.**
5 **Text File 2** for method), performed as in^{2,3,10}. The comparison used 83 samples from 42
6 patients (#F1a; #F1b) with confirmed SARS-CoV-2 infection detected by RT-PCR (**Table**
7 **S5**) and 500 pre-COVID-19 samples collected in 2017 (#F2). Spearman correlations
8 between the predicted positive ratio of our assay and the N, R, and S ELISA results were
9 between 0.81–0.82 for IgG and 0.56–0.80 for IgA, while IgM demonstrated the lowest
10 correlations characterized by values ranging between 0.17–0.44 (**Fig. 2c, Fig. S6b, Table**
11 **S7, and Supp. Text File 2** for the Methods).

12
13 To evaluate whether severely ill patients would demonstrate a specific antibody pattern,
14 we plotted the predictive positive ratios as a function of the severity of COVID-19 disease
15 (treated at home, hospitalized/non-Intensive Care Unit-ICU, and hospitalized/ICU) (**Fig.**
16 **2d**). Interestingly, ICU patients had higher anti-N protein IgG and IgA levels as compared
17 to the other groups, however, no definite conclusions can be drawn from these findings
18 due to the low number of samples.

19 Altogether, our findings highlight the flexibility and the utility of the mini-IFA method, as
20 well as the utility of the produced data.

21

1 **Conclusions**

2

3 The automated mini-IFA method enables high-throughput screening of antibodies from a
4 small volume of serum, with a performance comparable to ELISA, as exemplified here by
5 the analysis of serum specimens from SARS-CoV-2-infected patients. The assay can
6 simultaneously detect immune responses against multiple antigens and up to three Ig
7 classes, thus it can potentially improve diagnostic accuracy compared to single-antigen
8 tests. Antigen presentation by transient expression in cells allows 1) executing the assay
9 in a laboratory of low biosafety level, and 2) the use of complex antigens, including those
10 of any new virus variants, without the need of protein purification, thus it has the potential
11 to overcome the limitations of conventional IFA (for 1) and ELISA methods (for 2). New
12 ML model needs to be trained for each antigen. Here, we labelled on average 4,500 cells
13 in each antigen-antibody combination which took approximately a workday from an
14 expert. Cell -based format here was considered as the most physiological way to express
15 the antigens, as well as to reveal the information on their cellular localization, which is not
16 possible with ELISA or bead-based immunoassays. The benefit of the assay format over
17 ELISA or similar methods is there being no need to produce and purify the protein as the
18 cells are used to express the antigen. The additional benefits could include higher local
19 antigen concentration, better folding (although potentially distorted by fixation), and
20 detection of autoantibodies, as well as all the feature -based information the images can
21 provide for scientific studies.

22 A similar approach has been earlier suggested¹ and tested¹¹ for SARS-CoV-2 using alive
23 pathogen in BSL-3. Their analysis focuses on scoring the ratio of median antibody signal

1 between infected and non-infected cells and using this ratio in ROC analysis to set an
2 optimal threshold to deem sample either positive or negative for IgG, IgA, and IgM
3 antibodies separately. However, in their set-up, the response to virus as such (Pape et
4 al, 2020) does not reveal any specific responses to different virus antigens, whereas in
5 our assay, the measurements on different virus antigens can be used to differentiate
6 those only vaccinated (showing Igs only towards S protein/R antigen) and those who had
7 the earlier disease (showing Igs also to other virus proteins).

8
9 Another benefit of our new methodology is the simplified visualization of the results which
10 would enable a straightforward clinical application. End users of the assay can easily
11 compare the visualizations of the quantitative results to sample images. This facilitates
12 digital archiving, reduces bias caused by intra-/interobserver variability, as well as
13 reduces microscopy workload/time, and increases the reproducibility of the results. Thus,
14 the assay offers unique benefits compared to similar methods utilized for viral diagnostics,
15 which use live viruses, manual immunostaining of slides, and visual inspection by an
16 expert. The assay can be used, for example, for kinetic and longevity studies of antibody
17 responses induced by infections, and it could serve as a useful post-vaccination tool for
18 SARS-CoV-2 serosurveillance studies. Moreover, the assay could work with cells infected
19 with entire viruses in the early stages of any pandemic before the relevant viral antigens
20 are cloned. However, here we optimized the method for transfected antigens, as with
21 those, in addition to alleviating users from the requirement of high biosafety levels, we
22 can detect separate responses for each antigen, e.g. vaccinated from non-vaccinated but
23 infected.

1 The method described here allows the simultaneous quantitative determination of
2 responses against multiple antigens and different antibody classes in an automated
3 fashion, something not achievable using the classical methods, such as ELISA, widely
4 used in clinical practice. The combination of high throughput imaging and machine
5 learning makes the proposed assay highly beneficial over existing serological assays
6 because of its low cost, high sensitivity, and robustness. The richness of the data derived
7 from the images of antibody-antigen interactions gives orders of magnitude more
8 information, e.g., for studies of the immune responses to specific virus proteins, some of
9 which cannot be expressed in any other system. This is beneficial for any vaccine
10 development and understanding the immunogenic responses to infections.

11
12 As exemplified by the SARS-CoV-2, readily available, low-cost serology tests are key to
13 control epidemics. Our proof-of-concept study for automated mini-IFA serodiagnostics,
14 presented here, suggests that the assay translates to various pathogens with high-
15 potential for wide-scale research and clinical applications.

16

17 **Data Availability Statement**

18 Additional data are provided as supplemental data (tables, figures, and files). Scripts are
19 available at the GitHub repository: https://github.com/fimm-covid-19-hca/mini-IFA_paper.
20 Extracted single-cell features from microscopic images to train and test models are
21 available at Zenodo: <https://dx.doi.org/10.5281/zenodo.6352550>

1 **Supplementary Information**

2 The manuscript contains supplementary data: **a)** SI PDF file for Supplementary Text Files
3 1-3, Supplementary Figures S1-S9, Supplementary Tables S1-S8, as well as **b)**
4 Supplementary Data 1 (<https://fimm-covid-19-hca.github.io/>; for description, see the
5 the SI PDF) and **c)** Supplementary Data 2 (PDF file).

6

7 **Acknowledgements**

8 The authors thank Minerva Institute (Helsinki, Finland) for providing utilities for the project;
9 Prof. Perttu Hämäläinen (Aalto University, Finland) for providing expertise of his group for
10 the project, the FIMM High Throughput Biomedicine Unit for providing access to high-
11 throughput robotics, and the FIMM High Content Imaging and Analysis Unit for HC-
12 imaging and analysis (HiLIFE, University of Helsinki and Biocenter Finland). We
13 acknowledge support from the LENDULET-BIOMAG Grant (2018-342), from the
14 European Regional Development Funds (GINOP-2.3.2-15-2016-00006, GINOP-2.3.2-
15 15-2016-00026, GINOP-2.3.2-15-2016-00037), from the H2020-discovAIR (874656),
16 from the H2020 ATTRACT-SpheroidPicker, and from the Chan Zuckerberg Initiative,
17 Seed Networks for the HCA-DVP. The Finnish TEKES FiDiPro Fellow Grant 40294/13
18 (VP, OK, LP, PH), grants awarded by the Academy of Finland (iCOIN-336496: OK, VP,
19 OV; 308613: JH; 321809: TS; 310552: LP; 337530: IJ, FIRI2020-337036: FIMM-HCA,
20 AH, LP, VP, PH), the EU H2020 VEO project (OV) and Minerva Foundation for COVID-
21 19 research project grant (VP) are also greatly acknowledged. CG is funded by the
22 Academy of Finland Flagship programme, Finnish Center for Artificial Intelligence.
23 OrthoSera Ltd. was funded by NKFIH grants (2020-1.1.6-JÖVŐ-2021-00010, and

1 TKP2020-NKA-17). The authors thank Dora Bokor, PharmD, for proof-reading the
2 manuscript.

3

4 **Contributions**

5 JH, PH, and VP originally designed and led the project, and KrB, JH, PH, and VP
6 supervised the project. JH, EM, VP, MP, and LT designed the laboratory experiments and
7 JH, MH, AK, MP, EGyS, and LT executed the experiments. IJ and LKa provided
8 unpublished constructs. KaB, AKa, LKe, GT, AV, and OV provided serum samples; EF
9 and ZsL collected 165 positive sera with patient data and performed ELISA analyses in
10 Hungary in co-operation with Orthosera Ltd. AH, EM, LP, and MP performed high-content
11 imaging and JH, IJ, PK, LL, ES, and TS analysed IFA samples. CG, FK, and LP
12 developed the analysis pipeline. CG and LP facilitated the prediction model selection and
13 its comparison to ELISA and expert annotations. PH, AK, and FK developed the image
14 analysis software (BIAS). RH prepared the model for nuclei detection and segmentation.
15 SP prepared the QC and visualization scripts. AD, EM, and MP performed expert training.
16 CG, JH, MH, PH, LP, MP, and VP wrote the main parts of the manuscript. AD, CG, MH,
17 LP, MP, SP, VP and LT prepared the figures, tables and data files included in the paper.
18 All authors read, reviewed, and approved the final version of the manuscript.

19

20 **Competing Interests statement**

21 PH is the founder and shareholder, and AK and FK are employees of Single-Cell
22 Technologies Ltd. This study has been protected with invention disclosures (ID965/2020

1 and ID115/2021 University of Helsinki, Finland) and the patent applications have been filed
2 (Hungary; No. P2100295; International PCT/HU2022/050062).

3

4 **References**

- 5 1. Pape, C. *et al.* Microscopy-based assay for semi-quantitative detection of
6 SARS-CoV-2 specific antibodies in human sera: A semi-quantitative, high
7 throughput, microscopy-based assay expands existing approaches to measure
8 SARS-CoV-2 specific antibody levels in human sera. *BioEssays* **43**, 1–15
9 (2021).
- 10 2. Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in
11 humans. *Nat. Med.* **26**, 1033–1036 (2020).
- 12 3. Rusanen, J. *et al.* A 10-minute “mix and read” antibody assay for sars-cov-2.
13 *Viruses* **13**, 1–12 (2021).
- 14 4. Daly, J. L. *et al.* Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science*.
15 **370**, 861–865 (2020).
- 16 5. Mund, A. *et al.* AI-driven Deep Visual Proteomics defines cell identity and
17 heterogeneity Proteomics Program. *bioRxiv* 2021.01.25.427969 (2021),
18 accepted for publication in Nature Biotechnology.
- 19 6. Smith, K. *et al.* CIDRE: An illumination-correction method for optical
20 microscopy. *Nat. Methods* **12**, 404–406 (2015).
- 21 7. Hollandi, R. *et al.* nucleAIzer: A Parameter-free Deep Learning Framework for
22 Nucleus Segmentation Using Image Style Transfer. *Cell Syst.* **10**, 453-458.e6
23 (2020).

- 1 8. Piccinini, F. *et al.* Advanced Cell Classifier: User-Friendly Machine-Learning-
2 Based Software for Discovering Phenotypes in High-Content Imaging Data.
3 *Cell Syst.* **4**, 651-655.e5 (2017).
- 4 9. Smith, K. & Horvath, P. Active learning strategies for phenotypic profiling of
5 high-content screens. *J. Biomol. Screen.* **19**, 685–695 (2014).
- 6 10. Stadlbauer, D. *et al.* SARS-CoV-2 Seroconversion in Humans: A Detailed
7 Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr.*
8 *Protoc. Microbiol.* **57**, 1–15 (2020).
- 9 11. Tönshoff B. *et al.* Prevalence of SARS-CoV-2 Infection in Children and Their
10 Parents in Southwest Germany. *JAMA Pediatr.* **1**:175(6):586-593. (2021)

Figure 1.




Figure 1. a) Assay workflow. Shortly, Vero E6 cells, transfected to express SARS-CoV-2 antigens (N, M, R, and S), are fixed in 384-well plates for incubation with serum samples. The immunoglobulins (IgG, IgA, and IgM) are detected simultaneously with fluorophore-labelled secondary antibodies using automated high-content fluorescence microscopy. Machine learning is employed for (i) nuclei and cell segmentation, and (ii) phenotypic cell classification. The results are presented via a decision-support system, which also allows interactive visual observation of the raw images. For a full explanation with numbers, see the main text. **b)** Examples of microscopy images of specific IgG (DL550, orange), IgA (AF647, red), and IgM (AF488, green) responses against SARS-CoV-2 spike (S) protein in assay control serum samples obtained from positive (COVID-19+) and negative (COVID-19-) patients. (Scale bar in overview images: 100 μm ; zoom-in images: 10 μm .) **c)** Transfection efficiency of viral antigens is determined by immunostaining. Here, AF488-conjugated anti-HA (green) antibody for HA-tagged M protein and in-house rabbit anti-S antibody (AF488, green) for S protein are shown. Scale bars: 100 μm . **d)** Visualization of non-segmented and segmented cells. After segmentation of cell nuclei, an additional mask is created for the 'whole cell' by dilating the nucleus area for a maximum of 7 μm , and the 'cytoplasm' is determined as an area without the segmented nucleus. (Scale bars: 10 μm). **e)** Examples of manual labelling of cell classes for the training set. Cells were divided into five categories: positive, negative, atypical, small bright and trash.

Unless otherwise stated, the microscopy images presented show cells expressing the S protein of SARS-CoV-2, and they have been linearly adjusted from the original 16-bit image format to improve visual appearance.

Figure 2.




Figure 2. Performance of the assay. **a)** The dot plots show the distribution of sample prediction values of IgA and IgG antibody responses for S, R, N and M antigens present in the serum samples obtained from COVID-19 positive (COVID-19; collected in 2020) and negative (Neg; collected in 2017) patients. The sera obtained from COVID-19 positive patients are marked to show the time from a SARS-CoV-2 positive RT-PCR result. See Table S6 for the statistics. **b)** Comparison of the predicted values (IgG and IgA for N, S, and R antigens) with expert data, displayed as ROC curves. **c)** Correlation of the assay-predicted values (positivity ratios) with those of ELISA for IgG and IgA against the S and R antigens (high-throughput ELISA; n=42 COVID-19 patients, 80 samples; NEG n=80 patients, 80 samples), and against the N antigen (traditional ELISA; n=42 COVID-19 patients, 79 samples; NEG n=80 patients, 80 samples) antigens. ELISA values for the S/R vs. N antigen differ in scale, as they were obtained via chemiluminescence vs. colorimetric detection, respectively. See Table S7 for the statistics. **d)** Patient-specific antibody responses at different time points from the onset of symptoms or from obtaining a positive SARS-CoV-2 RT-PCR result plotted according to COVID-19 severity (treated at home, hospitalized/non-ICU, and hospitalized/ICU).